SubrenaI CapsuIe Tumor ImpIant Assay with Frozen Tumor Tissue: A Preliminary Study Using Mouse Sareoma and Human Uterine Cervix Cancer

Abstract

The purpose of this study is to evaluate the possibility of application of SHeA to previously frozen tumor tissue. Mouse sarcoma-I80 and human squamous cell carcinoma of the uterine cervix were used as implanting tumor specimens. The fresh tumor specimens were frozen by rapid freezing method and stored in a liquid nitrogen tank. On the 7th day of freezing, the specimens were thawed and diced into 1 cubic millimeter pieces, and implanted beneath the subrenal capsule of ICH mice. The average viabilities before freezing and after thawing were 86.7% and 10.5% in mouse sarcoma-I80 respectively. And those of human uterine cervix cancer were 73.3% and 9.5% respectively. The evaluability of implanted tumor was 83.3% on the 6th day and 73.7% on the 12th day in mouse sarcoma, and in human cervix cancer, 75.0% and 66.7% respectively. The growth of previously frozen implanted mouse sarcoma was significant, 2.1 times on the 6th day and 73.9 times on the 12th day in volume. In the case of cervix cancer, the previously frozen tumor implants also grew significantly, 1.7 times on the 6th day and 2.1 times on the 12th day in volume. In conclusion, this preliminary laboratory study showed that SHCA could be applied to frozen tumor tissue as well as to fresh tissue for chemosensitivity test.